"For the twelve months ending September 2011, Dilaudid(R) 8 mg tablets and its generic equivalents had total U.S. sales of approximately $30 million according to IMS Health Data. and there are currently four other approved generic manufacturers plus the innovator.
So with Elite there are six companies to split up the $30,000,000 market. Elite's partner, TAGI, would do well to see $2,000,000 in SALES, NOT PROFIT. Plus Elite only gets a piece of the sales in the form of a license fee + the milestone payments.
This won't boost the PPS much. We need several more announcements and a good 10Q to get going.